Friday, September 25, 2026

5 minute market report (Sept 25)

Good morning,


If you’ve been following the markets as closely as we do, you’ve seen some pretty interesting developments even aside from The Fed’s landmark interest rate decision, and the crypto bull run that’s got smart investors ready to cash in.


Growth slowed down to a crawl in the second quarter. Corporate profits climbed by a massive margin.


The Federal Reserve quietly reviewed discount rates behind closed doors.


These three updates look disconnected on the surface. They actually describe an economy where large institutions hoard cash while actual economic momentum cools off for everyone else.


The Deceleration Gap

Real gross domestic product increased at an annual rate of 1.5 percent in the second quarter of 2026.


That is a noticeable drop from the 2.1 percent growth recorded in the first quarter.


Consumer spending and exports tried to keep the engine running. Government spending turned negative and slowed down the entire machine.


The Corporate Profit Surge

Profits from current production jumped by $400.9 billion in the second quarter. That dwarfs the modest $74.4 billion increase seen in the first quarter.


Big companies are extracting wider margins even while broader economic growth cools down. They are cutting costs and protecting their balance sheets.


The Discount Window Signal

Federal Reserve discount rate meetings in late July show officials tracking institutional liquidity pressures closely. Central bankers monitor these plumbing mechanisms when commercial lenders face tighter liquidity constraints.


That underlying stress kinda goes against the calm surface of the broader equities market.


What This Means To You As An Investor

Growth is slowing down while corporate profits go up. That divergence creates hidden dangers for your retirement savings - as if you need more, am I right?


Here’s a few of them:


The Margin Squeeze: Companies with weak pricing power will struggle as overall economic momentum slows down.


The Cash Buffer: Holding adequate cash reserves protects you when corporate earnings diverge from real economic health.


The Safety Trade: Quality assets with strong balance sheets outperform speculative plays when growth decelerates.


Where Crypto Fits Into This Picture

Digital assets remain insulated from traditional GDP deceleration metrics. They follow global liquidity shifts rather than domestic quarterly growth numbers.


That independence cuts both ways when macro volatility hits.


The Crypto and AI Reality

Advanced technology infrastructure requires heavy capital expenditure regardless of slowing GDP growth. Institutional players keep funding these buildouts even as consumer spending softens.


Technology hardware demand stays high while traditional economic indicators flash warning signs.


Rules are shifting underneath your feet while traditional pundits tell you to stay the course. 


If you don’t take advantage of opportunities when they come along, how will you grow your wealth to the point where you can retire comfortably (or at all) and leave a legacy for your family?


That’s why I mentioned the crypto bull run earlier in this newsletter.


Basically, it’s still in the early stages which means YOU can cash in this time, instead of watching everybody else make out like bandits.


But you need to know exactly what’s happening and what to do next.


That’s why we’re holding a free live briefing on Sunday to reveal everything.


The room’s almost booked out so click here to secure your spot now.


To your financial freedom,

Iman




Fall Into Savings 🍁

Welcome to Fall with 15% off site-wide on orders over $50 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

Fwd: Your withdrawal request

Hello ,


Your withdrawal request has been validated.


>>> Click here to confirm the withdrawal of your money to your account



















Unsubscribe Here


Brandson LLC
Written with passion
FAIRFAX, VIRGINIA 22033
United States


MAJOR BUY ALERT: $126 Trillion Shift… $15 stock

Named the #1 stock picker of 2020 by TipRanks, Luke Lango has identified 40 stocks before they soared by 1,000% or more. Today he’s betting his reputation on a $15 stock… at the center of a $126 trillion shift.

How A Small Company (Nasdaq: NTRB) Built Global Patent Protection Around Its Technology

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

How A Small Company (Nasdaq: NTRB) Built Global Patent Protection Around Its Technology


*Click Here To Get Our Alerts Faster Via SMS*


September 25th

Greetings Readers,


Every pharma story has a quiet turning point.


For Nutriband Inc. (Nasdaq: NTRB), it may have arrived in a letter from the U.S. Patent and Trademark Office.


The company received a USPTO Notice of Publication for the commercial brand name trademarks of its lead product, an abuse-deterrent fent-a-nyl patch. The notice starts a 30-day opposition window. If no objections are filed, Nutriband says the USPTO is expected to issue a Notice of Allowance.


Why does a name matter?


You don't brand a product you plan to shelve. Nutriband intends to submit the name and product labeling to the FDA and other international agencies for review.


The patch runs on AVERSA™, a platform with issued patents in 46 countries, including the U.S., Europe, Japan, China and Canada.


A Health Advances analysis cited by the company points to potential peak annual U.S. sales of $80Mn to $200Mn.

Nutriband's brand name trademarks entered USPTO publication. Source: Nutriband Inc.

About Nutriband Inc. (Nasdaq: NTRB)


Nutriband is an Orlando-based developer of transdermal pharmaceutical products. 

Its latest quarterly filing describes two engines.


4P Therapeutics leads AVERSA development.


Pocono Pharmaceuticals, a contract manufacturer of topical, transdermal and kinesiology tape products, generates current revenue.


The development pipeline reaches beyond fent-a-nyl. AVERSA Buprenorphine and AVERSA Methylphenidate, and 4P Exenatide for type 2 diabetes sit in preclinical stages.


Manufacturing partner Kindeva completed commercial scale-up of the fent-a-nyl patch in 2025.


Sources And More: NTRB Website.

The Market Backdrop: Patches Are Growing Up


Precedence Research sizes the global transdermal delivery systems market at $87.46Bn in 2026, with a potential climb to $239.43Bn by 2035. That's an 11.84% CAGR. North America held a 38.60% share in 2025.


Abuse risk concentrates in pain management. Nutriband's corporate presentation states that over 70% of fent-a-nyl patch abusers choose oral routes.


AVERSA's taste-aversion approach targets that exact pathway.

Global transdermal delivery systems market forecast, 2025 to 2035. Source: Precedence Research

Behind The Scenes: The Shareholder Meeting Checklist


At the January shareholder annual meeting in Orlando, management walked shareholders through a scorecard. The meeting summary credited 2025 with a stronger Kindeva partnership, completed scale-up, new U.S. and Macao patents, and an FDA Type C meeting.


The 2026 focus on development towards NDA filing list was just as direct:


  • File nonprovisional patent application to potentially extend patent protection of AVERSA™ technology-based products to 2046
  • Manufacture clinical supplies for the Human Abuse Liability (HAL) clinical trial
  • File Investigational New Drug (IND) application with the US FDA
  • Initiate Human Abuse Liability (HAL) clinical study


Shareholders also elected two new directors, Alessandro Puddu and Viorica Carlig. 


For a development-stage company, a written roadmap like this gives you something concrete to measure progress against.

The Pivot: AVERSA Heads Abroad


Nutriband then looked south. It signed an exclusive distribution agreement with Innomedica for Costa Rica, covering AVERSA Fent-a-nyl upon approval and all of its sports tape products. Innomedica oversees and finances the regulatory approvals.


Later, the company announced its AI kinesiology tapes were approved for distribution and sale in Costa Rica. The tape line gets a foreign foothold today, while the patch gains a ready channel for later.

Nutriband's exclusive Costa Rica agreement with Innomedica. Source: Nutriband Inc.

NTRB's IPO Warrant Overhang Faces A Hard Stop September 30th


Capital structure often gets overlooked until it changes. At Nutriband, a change is now close.


The company's outstanding 2021 IPO warrants, 910,904 in total with a $6.43 exercise price, are set to expire on September 30th, 2026.


Management has confirmed there will be no extension, repricing, or modification of these terms. Holders either exercise before expiration, or the warrants lapse.


Why does this matter? For years, these warrants have represented a known source of potential dilution. Their expiration could remove that overhang entirely.


The potential result for NTRB is a cleaner share structure.

6 Potential Catalysts Putting (Nasdaq: NTRB) At The Top Of Our Watchlist


#1. A Low Float Setup With Heightened Volatility Potential. With Yahoo Finance reporting a float of just 5.28Mn shares, NTRB fits the low float profile, and the potential for heightened volatility may be significant.


#2. Twelve Of Thirteen Technical Indicators Flashing Bullish. Barchart's opinion page showed an 88% overall bullish reading for NTRB at the closing bell Thursday.


#3. Brand Name Trademarks Enter The USPTO Opposition Window. A Notice of Allowance could follow if no objections are filed, potentially moving NTRB closer to submitting its brand name to the FDA.


#4. A Warrant Deadline Carrying $5.86Mn In Potential Proceeds. The company confirmed its 910,904 public warrants at $6.43 expire Sept. 30 without extension or repricing, and NTRB's latest close sits above that strike.


#5. A Pipeline Stretching From Pain To ADHD And Diabetes. Beyond fent-a-nyl, the NTRB pipeline includes AVERSA Buprenorphine, AVERSA Methylphenidate and 4P Exenatide, potentially extending the platform into new categories.


#6. Insiders Hold A Commanding Share Of The Company. Insiders own approx. 59.09% of NTRB shares on Yahoo Finance, a level of alignment market watchers often track closely.

The Bottom Line


Nutriband Inc. (Nasdaq: NTRB) isn't a finished story.


It's a company with a patented platform, a named product, a manufacturing partner, and a published regulatory roadmap.


The next steps are public: clinical supplies, an IND, and a human abuse liability study.


We’re initiating coverage on Nutriband Inc. (Nasdaq: NTRB).


Keep your eyes peeled for updates coming out soon. Talk again shortly.


Sincerely,

Kai Parker

StockWireNews


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)


*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.


Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 09/24/2026 and ending on 09/28/2026 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred sixty five thousand USD ("Funds"). These Funds were part of the one hundred thirty four thousand USD funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US).


Neither SWN Media LLC, TD Media LLC and their member own shares of (NTRB:US).


Please see important disclosure information here: https://stockwirenews.com/disclosure/ntrb-elb0m/#details

5 minute market report (Sept 25)

...